Intrauterine growth restriction (IUGR) detection refers to the combined clinical and laboratory assessment used to identify fetuses that fail to achieve their expected growth potential in utero. Timely and accurate detection through ultrasound biometry, Doppler velocimetry, and maternal serum biomarker analysis is essential for reducing the risks of stillbirth, neonatal complications, and long-term developmental disorders. This technical article provides a comprehensive overview of the sample types, testing parameters, analytical methods, and clinical applications involved in modern IUGR screening and diagnosis.
Technical Overview
Intrauterine growth restriction (IUGR), also referred to as fetal growth restriction (FGR), is defined as a failure of the fetus to attain its genetically predetermined growth potential. In clinical practice, IUGR is suspected when the estimated fetal weight (EFW) or abdominal circumference (AC) falls below the 10th percentile for gestational age, with severe restriction typically defined as below the 3rd percentile. The condition affects approximately 5–10% of pregnancies worldwide and is one of the leading contributors to perinatal morbidity, stillbirth, neonatal intensive care admission, and long-term cardiovascular and metabolic disease risk.
IUGR is classified into two principal phenotypes. Symmetric (type I) IUGR, accounting for roughly 20–30% of cases, manifests in early pregnancy with proportionally reduced growth of the head, abdomen, and long bones, and is frequently associated with chromosomal abnormalities, genetic syndromes, congenital infection, or early teratogenic exposure. Asymmetric (type II) IUGR, representing 70–80% of cases, typically presents in the late second or third trimester with relative preservation of head circumference and reduced abdominal circumference, reflecting placental insufficiency and chronic nutrient-oxygen deprivation.
The principal etiological categories include maternal factors (chronic hypertension, preeclampsia, pregestational diabetes with vascular disease, malnutrition, anemia), placental factors (infarction, abnormal trophoblast invasion, velamentous cord insertion), fetal factors (aneuploidy, structural anomalies, multiple gestation, congenital infection), and environmental factors (smoking, alcohol, hypoxia, and certain medications). Because the majority of affected fetuses are structurally normal and clinically silent until advanced stages, structured screening and diagnostic testing are critical to management.
Detection programs are built upon a multidisciplinary testing framework combining imaging, maternal serum biochemistry, genetic analysis, and microbiological screening. Clinical laboratories supporting these programs are expected to operate under recognized quality management frameworks, such as ISO 15189 for medical laboratories, while ultrasound equipment and in vitro diagnostic reagents should conform to ISO 13485 quality system requirements and applicable national medical device regulations.
Testing Samples
Maternal Blood Serum
Maternal venous blood is collected to quantify placental and fetoplacental biomarkers, including pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), alpha-fetoprotein (AFP), free beta-human chorionic gonadotropin (free β-hCG), unconjugated estriol (uE3), and inhibin A. Serum is also used for cell-free fetal DNA (cffDNA) analysis and for infectious disease serology. Samples are typically collected into serum separator tubes, centrifuged promptly, and analyzed fresh or stored at 2–8°C for short-term or at −70°C for long-term preservation.
Maternal Urine
A midstream or catheterized urine specimen is used to assess the protein-to-creatinine ratio and to screen for proteinuria, a key indicator of hypertensive disorders of pregnancy that are strongly associated with placental-mediated IUGR. Urinary analysis assists in differentiating isolated growth restriction from growth restriction complicated by preeclampsia.
Amniotic Fluid
Amniotic fluid obtained by ultrasound-guided amniocentesis is used for fetal karyotyping, chromosomal microarray analysis (CMA), fluorescence in situ hybridization (FISH), quantitative fluorescence polymerase chain reaction (QF-PCR), and PCR-based detection of congenital infections such as cytomegalovirus and toxoplasmosis. Amniocentesis is generally performed after 15 weeks of gestation when genetic confirmation is indicated.
Chorionic Villus and Umbilical Cord Blood Samples
Chorionic villus sampling (CVS), performed between 10 and 13 weeks of gestation, provides placental tissue for rapid aneuploidy testing and molecular genetic studies in early-onset or structurally abnormal cases. Percutaneous umbilical cord blood sampling (cordocentesis) may be employed in selected late-gestation cases to assess fetal karyotype, hemoglobin, acid-base status, and platelet count when rapid diagnostic information is required.
Ultrasound and Doppler Imaging Data
Two-dimensional sonographic biometric measurements, Doppler flow velocity waveforms, and cardiotocographic tracings constitute the primary imaging data set for growth surveillance. Standardized acquisition and archival of these images are essential for longitudinal percentile tracking and for audit against recognized fetal growth standards.
Placental Tissue
Following delivery, placental tissue and umbilical cord segments are submitted for histopathological examination. Findings such as maternal vascular malperfusion, fetal thrombotic vasculopathy, chronic villitis, and villous maturation defects provide retrospective etiological confirmation and inform counseling regarding recurrence risk in future pregnancies.
Testing Items
Core testing items for IUGR detection span sonographic, hemodynamic, biochemical, genetic, and microbiological domains. The following items are commonly evaluated in a structured diagnostic workflow:
- Estimated fetal weight (EFW) percentile calculated using standardized biometric formulas (e.g., Hadlock) against international fetal growth standards.
- Biometric indices: biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), femur length (FL), and derived ratios (HC/AC, FL/AC).
- Amniotic fluid volume assessment: amniotic fluid index (AFI) and maximum vertical pocket (MVP).
- Umbilical artery Doppler indices: pulsatility index (PI), resistance index (RI), systolic-to-diastolic (S/D) ratio, and evaluation of absent or reversed end-diastolic flow (AREDF).
- Middle cerebral artery (MCA) Doppler: pulsatility index and peak systolic velocity (PSV) for assessment of brain-sparing redistribution and fetal anemia.
- Cerebroplacental ratio (CPR), calculated as MCA PI divided by umbilical artery PI.
- Ductus venosus Doppler: pulsatility index and a-wave morphology as markers of cardiac decompensation.
- Uterine artery Doppler: mean pulsatility index and presence of bilateral notching for first and second trimester prediction of placental insufficiency.
- Maternal serum biomarkers: PAPP-A, PlGF, sFlt-1, sFlt-1/PlGF ratio, AFP, free β-hCG, uE3, and inhibin A, expressed as multiples of the median (MoM).
- Genetic testing: conventional karyotype (G-banding), chromosomal microarray analysis, targeted FISH or QF-PCR for common aneuploidies, and non-invasive prenatal testing (NIPT) via maternal plasma cffDNA.
- Congenital infection screening: TORCH panel serology (IgM, IgG, and IgG avidity) and confirmatory PCR on amniotic fluid for Toxoplasma gondii, rubella virus, cytomegalovirus, and herpes simplex virus.
- Fetal well-being indices: cardiotocography (non-stress test), biophysical profile score (BPS), and modified biophysical profile.
- Postnatal placental histopathology for etiological classification and recurrence risk stratification.
Testing Methods
Ultrasound Biometry and Growth Charting
Standardized two-dimensional ultrasound measurement of BPD, HC, AC, and FL is performed by credentialed sonographers using calibrated equipment. EFW is derived from established regression formulas and plotted on validated growth charts, such as the INTERGROWTH-21st and WHO international fetal growth standards, or on customized population-specific charts that adjust for maternal height, weight, parity, and ethnicity. Serial scans are scheduled at intervals of no less than two weeks, since shorter intervals increase the probability of apparent growth aberration caused by measurement error, which is typically ±10–15% for EFW.
Doppler Velocimetry
Spectral Doppler interrogation of the umbilical artery, middle cerebral artery, ductus venosus, and uterine arteries provides functional assessment of fetoplacental circulation. Elevated umbilical artery PI with progression to absent or reversed end-diastolic flow indicates escalating placental vascular resistance and fetal compromise. Reduced MCA PI reflects hemodynamic centralization (brain-sparing effect), while an elevated ductus venosus PI or reversed a-wave signals deterioration toward cardiac decompensation and demands expedited delivery planning.
Maternal Serum Biomarker Assays
Serum biomarkers are quantified using automated immunoassay platforms, including chemiluminescent immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and electrochemiluminescence (ECLIA). First trimester PAPP-A below approximately 0.4 MoM and low free β-hCG are associated with elevated risk of placental-mediated growth restriction. Second trimester low PlGF, elevated sFlt-1, and an sFlt-1/PlGF ratio exceeding validated thresholds indicate angiogenic imbalance consistent with placental insufficiency. Results are interpreted alongside gestational age, maternal characteristics, and imaging findings within risk-algorithm software validated for the local population.
Genetic and Cytogenetic Analysis
Non-invasive prenatal testing based on massively parallel sequencing of maternal plasma cffDNA serves as a screening tool for common aneuploidies when early-onset IUGR is accompanied by elevated risk indicators. Definitive cytogenetic diagnosis is obtained through amniocentesis or CVS with G-banded karyotyping, complemented by chromosomal microarray analysis, which additionally detects submicroscopic copy number variations and uniparental disomy associated with early-onset growth restriction.
Infectious Agent Screening
Serological screening for TORCH agents employs immunoassay detection of specific IgM and IgG antibodies, with IgG avidity testing used to distinguish recent from past infection. Positive or equivocal findings are confirmed by nucleic acid amplification testing (PCR) on amniotic fluid, with quantitative viral load determination guiding fetal prognosis and potential antiviral therapy in cases such as congenital cytomegalovirus infection.
Fetal Well-Being Assessment
Cardiotocography evaluates fetal heart rate baseline, variability, accelerations, and decelerations, while the biophysical profile combines the non-stress test with sonographic assessment of fetal breathing movements, gross body movements, fetal tone, and amniotic fluid volume. These methods determine surveillance frequency and inform the timing of delivery in confirmed growth-restricted pregnancies.
Applications
IUGR detection programs are applied across a wide spectrum of clinical and research settings, supporting risk stratification, individualized surveillance, and evidence-based intervention timing. Principal applications include:
- First trimester combined screening and uterine artery Doppler assessment to identify pregnancies at high risk of subsequent placental insufficiency.
- Serial surveillance of fetuses with confirmed or suspected growth restriction to monitor deterioration and guide delivery timing.
- Differential diagnosis between small-for-gestational-age (SGA) constitutionally small fetuses and pathologically growth-restricted fetuses requiring intervention.
- Etiological workup of early-onset IUGR, including aneuploidy screening, chromosomal microarray analysis, and congenital infection testing.
- Management of high-risk pregnancies complicated by chronic hypertension, preeclampsia, antiphospholipid syndrome, pregestational diabetes, or advanced maternal age.
- Neonatal care planning, including anticipation of complications such as hypoglycemia, hypothermia, polycythemia, and perinatal asphyxia.
- Post-delivery placental histopathological correlation and long-term follow-up planning for neurodevelopmental and cardiometabolic risk.
- Epidemiological research, fetal growth standard development, and audit of perinatal outcomes within quality management frameworks.
- Support for clinical laboratories and accredited third-party laboratories developing validated prenatal diagnostic panels under ISO 15189 quality systems.
FAQ
What is the difference between small for gestational age (SGA) and IUGR?
SGA is a descriptive term for fetuses whose estimated weight is below the 10th percentile, which includes constitutionally small but healthy fetuses. IUGR or fetal growth restriction implies a pathological process in which the fetus fails to achieve its intrinsic growth potential, often accompanied by abnormal Doppler indices, reduced growth velocity, or biomarker evidence of placental dysfunction.
When should IUGR screening begin?
Risk assessment begins at the first trimester combined screening visit (11–13+6 weeks), incorporating maternal history, serum PAPP-A and free β-hCG, and, in high-risk populations, uterine artery Doppler at 20–24 weeks. Any fetus with an EFW or AC below the 10th percentile should enter a structured surveillance pathway.
How accurate is ultrasound in estimating fetal weight?
Ultrasound-based EFW carries a typical random error of ±10–15% relative to birth weight. Accuracy is improved through standardized measurement protocols, calibrated equipment, appropriate growth charts, and serial scanning at intervals of at least two weeks to distinguish true growth restriction from measurement variability.
What do abnormal Doppler findings indicate?
Elevated umbilical artery PI with absent or reversed end-diastolic flow indicates progressive placental vascular insufficiency. A low middle cerebral artery PI with reduced cerebroplacental ratio reflects blood flow redistribution to the brain, while abnormal ductus venosus waveforms indicate advanced fetal compromise that usually requires admission, intensified monitoring, and consideration of delivery.
Are maternal serum biomarker tests safe?
Yes. Maternal serum assays are performed on a routine venous blood sample and pose no risk to the mother or fetus. They provide predictive and diagnostic information that complements imaging but must always be interpreted together with ultrasound findings and clinical context.
Does amniocentesis carry risks when IUGR is suspected?
Amniocentesis is an invasive procedure with a procedure-related pregnancy loss rate generally reported in the range of 0.1–0.5%. Its use is reserved for cases in which genetic diagnosis will materially change management, such as early-onset IUGR, structural anomalies, or suspected congenital infection, and it is performed under continuous ultrasound guidance by experienced operators.
Can IUGR be treated before birth?
There is no curative intrauterine therapy for most forms of IUGR. Management focuses on close surveillance, optimization of maternal health, correction of modifiable factors such as smoking, timely administration of corticosteroids for lung maturation, and carefully timed delivery to balance the risks of prematurity against the risks of continued intrauterine compromise.
How frequently should growth-restricted fetuses be monitored?
Monitoring frequency is individualized according to severity and gestational age. Typical protocols combine growth scans every two to three weeks with weekly or twice-weekly umbilical artery and ductus venosus Doppler studies, cerebroplacental ratio assessment, and cardiotocography or biophysical profile until delivery is indicated.